ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $144,713 | -9.4% | 6,944 | +4.1% | 0.01% | 0.0% |
| Q2 2023 | $159,794 | +27.3% | 6,672 | 0.0% | 0.01% | +33.3% |
| Q1 2023 | $125,567 | +6.1% | 6,672 | -10.2% | 0.01% | +20.0% |
| Q4 2022 | $118,333 | +1.1% | 7,433 | +3.9% | 0.01% | -16.7% |
| Q3 2022 | $117,056 | +6.7% | 7,155 | -8.1% | 0.01% | +20.0% |
| Q2 2022 | $109,677 | -41.8% | 7,784 | 0.0% | 0.01% | -28.6% |
| Q1 2022 | $188,528 | -74.0% | 7,784 | -74.9% | 0.01% | -30.0% |
| Q4 2021 | $724,684 | +32.3% | 31,049 | -5.9% | 0.01% | +25.0% |
| Q3 2021 | $547,931 | -31.9% | 32,988 | 0.0% | 0.01% | -27.3% |
| Q2 2021 | $804,577 | +287.8% | 32,988 | +310.2% | 0.01% | +266.7% |
| Q1 2021 | $207,484 | -53.8% | 8,042 | -4.3% | 0.00% | -57.1% |
| Q4 2020 | $449,278 | +27.1% | 8,404 | -1.9% | 0.01% | +16.7% |
| Q3 2020 | $353,389 | -16.1% | 8,567 | -1.4% | 0.01% | -14.3% |
| Q2 2020 | $421,107 | -70.4% | 8,688 | -74.2% | 0.01% | -76.7% |
| Q1 2020 | $1,423,572 | -3.4% | 33,694 | -2.2% | 0.03% | +25.0% |
| Q4 2019 | $1,473,685 | +22.9% | 34,448 | +3.4% | 0.02% | +20.0% |
| Q3 2019 | $1,199,223 | +24.9% | 33,321 | -7.2% | 0.02% | +25.0% |
| Q2 2019 | $960,168 | -0.4% | 35,921 | 0.0% | 0.02% | -5.9% |
| Q1 2019 | $964,479 | +84.3% | 35,921 | +11.0% | 0.02% | +70.0% |
| Q4 2018 | $523,213 | -22.1% | 32,357 | 0.0% | 0.01% | -16.7% |
| Q3 2018 | $671,731 | -99.9% | 32,357 | 0.0% | 0.01% | +50.0% |
| Q2 2018 | $494,091,000 | +199.5% | 32,357 | +340.7% | 0.01% | +300.0% |
| Q1 2018 | $164,975,000 | +74549.3% | 7,342 | +0.0% | 0.00% | -33.3% |
| Q4 2017 | $221,000 | -19.3% | 7,341 | +0.8% | 0.00% | +50.0% |
| Q3 2017 | $274,000 | +42.0% | 7,282 | +5.4% | 0.00% | +100.0% |
| Q2 2017 | $193,000 | -14.6% | 6,910 | +5.2% | 0.00% | -50.0% |
| Q1 2017 | $226,000 | +19.6% | 6,568 | 0.0% | 0.00% | +100.0% |
| Q4 2016 | $189,000 | -13.3% | 6,568 | -4.3% | 0.00% | -50.0% |
| Q3 2016 | $218,000 | -1.4% | 6,865 | +1.0% | 0.00% | 0.0% |
| Q2 2016 | $221,000 | -86.8% | 6,799 | -88.7% | 0.00% | -84.6% |
| Q1 2016 | $1,677,000 | -15.2% | 59,963 | +8.1% | 0.01% | -13.3% |
| Q4 2015 | $1,977,000 | +7.8% | 55,446 | 0.0% | 0.02% | +15.4% |
| Q3 2015 | $1,834,000 | -21.7% | 55,446 | -0.9% | 0.01% | -18.8% |
| Q2 2015 | $2,343,000 | +16.7% | 55,942 | -9.2% | 0.02% | +6.7% |
| Q1 2015 | $2,007,000 | +2.1% | 61,579 | -0.5% | 0.02% | +7.1% |
| Q4 2014 | $1,965,000 | +28.3% | 61,878 | 0.0% | 0.01% | +27.3% |
| Q3 2014 | $1,532,000 | +9.6% | 61,878 | 0.0% | 0.01% | +10.0% |
| Q2 2014 | $1,398,000 | -7.1% | 61,878 | 0.0% | 0.01% | 0.0% |
| Q1 2014 | $1,505,000 | +7.3% | 61,878 | +10.2% | 0.01% | 0.0% |
| Q4 2013 | $1,403,000 | -9.0% | 56,132 | 0.0% | 0.01% | -16.7% |
| Q3 2013 | $1,542,000 | +51.3% | 56,132 | 0.0% | 0.01% | +50.0% |
| Q2 2013 | $1,019,000 | – | 56,132 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |